Published in Ann Intern Med on July 01, 1966
Unifocal bone findings by scintigraphy. Clinical significance in patients with known primary cancer. West J Med (1978) 0.93
[Sequential survey of bone metastases in mammary cancer with 87m Sr and its therapeutic implications]. Arch Orthop Unfallchir (1972) 0.80
Radioisotope scanning of brain, liver, lung and bone with a note on tumour localizing agents. Postgrad Med J (1973) 0.75
Prediction of myelotoxicity using semi-quantitative marrow image scores. J Nucl Med (1997) 1.94
Clinical assessment of left ventricular regional contraction patterns and ejection fraction by high-resolution gated scintigraphy. J Nucl Med (1975) 1.48
The ventilatory lung scan in the diagnosis of pulmonary embolism. N Engl J Med (1970) 1.44
Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice. J Nucl Med (1988) 1.17
Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung. J Nucl Med (1994) 1.15
NanoFerrite particle based radioimmunonanoparticles: binding affinity and in vivo pharmacokinetics. Bioconjug Chem (2008) 1.11
A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates. Cancer (1994) 1.09
Potential use of amino acid cocktails to reduce renal tubular reabsorption of radioconjugates. J Nucl Med (1996) 1.08
Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice. Cancer Biol Ther (2008) 1.07
Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res (1995) 1.06
Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci U S A (1997) 1.04
Review of a 5-year experience with the radiostrontium bone scintiscan. Calif Med (1972) 1.02
Scintigraphy in the diagnosis of osteonecrosis. Clin Orthop Relat Res (1978) 1.02
Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy. J Nucl Med (1988) 1.01
Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy. Cancer Biother Radiopharm (2001) 1.01
Serum stability of 67Cu chelates: comparison with 111In and 57Co. Int J Rad Appl Instrum B (1986) 1.00
Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients. Nucl Med Biol (1999) 0.99
Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med (1990) 0.97
Scintigraphic imaging of a blind-ending ureteral duplication. J Nucl Med (1975) 0.96
Radioimmunotherapy: recent results and future directions. J Clin Oncol (1996) 0.96
Assessment of conventional criteria for the early diagnosis of thrombophlebitis with the 125I-fibrinogen uptake test. Radiology (1977) 0.96
Comparative serum stability of radiochelates for antibody radiopharmaceuticals. J Nucl Med (1987) 0.94
Vascularity of the femoral head. Tc diphosphonate scintigraphy validated with tetracycline labeling. Clin Orthop Relat Res (1977) 0.94
Blood flow in irradiated mouse sarcoma as determined by the clearance of xenon-133. Cancer Res (1972) 0.94
85 Sr bone scan in neoplastic disease. Semin Nucl Med (1972) 0.93
Quantitative bremsstrahlung imaging of yttrium-90 using a Wiener filter. Med Phys (1994) 0.92
Radionuclide assessment of nitroglycerin influence on abnormal left ventricular segmental contraction in patients with coronary heart disease. Circulation (1976) 0.91
Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med (1999) 0.90
A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. J Nucl Med (1999) 0.90
Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy. Int J Rad Appl Instrum B (1991) 0.90
A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy. Nucl Med Biol (1996) 0.89
Hepatic scintiangiographic patterns. Radiology (1974) 0.88
Sodium flux in myotonic muscular dystrophy. Am J Physiol (1968) 0.88
Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy. Cancer Biother Radiopharm (2001) 0.88
Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies. Int J Cancer Suppl (1988) 0.87
Critical evaluation of hepatic scintiangiography for neoplastic tumors of the liver. J Nucl Med (1975) 0.87
New approach to interpretation of technetium-99m pyrophosphate scintigraphy in detection of acute myocardial infarction: clinical assessment of diagnostic accuracy. Am J Cardiol (1977) 0.87
Origin and evolution of radioactive pulmonary emboli in man. Radiology (1968) 0.86
L6 monoclonal antibody binds prostate cancer. Prostate (1998) 0.85
Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy. Cancer Biother Radiopharm (2000) 0.85
Detection of bone lesions with the strontium-85 scintiscan. J Nucl Med (1966) 0.84
The biologic window for chimeric L6 radioimmunotherapy. Cancer (1994) 0.84
Scintiscanning in malignant lymphomatous involvement of bone. Arch Intern Med (1968) 0.84
Trials and tribulations: oncological antibody imaging comes to the fore. Semin Nucl Med (1997) 0.83
Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates. J Nucl Med (1998) 0.83
Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res (1995) 0.83
Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies. Int J Biol Markers (1988) 0.83
Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies. J Nucl Med (1996) 0.83
Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer. Clin Cancer Res (2001) 0.82
Evaluation of the liver and spleen in Hodgkin's disease. I. The value of hepatic scintigraphy. Am J Med (1972) 0.82
Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol Immunother (1996) 0.82
Cell-mediated immunity in severely head-injured patients: the role of suppressor lymphocytes and serum factors. J Neurosurg (1992) 0.82
Metabolism of indium chelates attached to monoclonal antibody: minimal transchelation of indium from benzyl-EDTA chelate in vivo. J Nucl Med (1990) 0.81
Pulmonary function studied with the xenon-133 scanning technique. Normal values and a postural study. Am Rev Respir Dis (1966) 0.81
Immunochemical aspects of monoclonal antibodies important for radiopharmaceutical development. Int J Rad Appl Instrum B (1986) 0.81
Comparison of radiolabeled bleomycins and gallium citrate in tumor-bearing mice. J Nucl Med (1977) 0.81
Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts. Cancer Biother Radiopharm (1998) 0.81
Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. J Nucl Med (1997) 0.81
67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. J Nucl Med (1999) 0.81
Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources. J Nucl Med (1997) 0.81
Technetium-99m pyridoxylideneglutamate (P.G.) cholescintigraphy. Radiology (1976) 0.81
Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma. Cancer (1997) 0.80
Radioisotope ventriculography in the Arnold-Chiari malformation. Radiology (1969) 0.80
Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice. J Nucl Med (1995) 0.80
I-fibrinogen as an oncophilic radiodiagnostic agent: distribution kinetics in tumour-bearing mice. Br J Cancer (1977) 0.79
Radioimmunotherapy for breast cancer: treatment of a patient with I-131 L6 chimeric monoclonal antibody. Int J Biol Markers (1992) 0.79
Critical Lym-1 binding residues on polymorphic HLA-DR molecules. Mol Immunol (1999) 0.79
Effect of mass of 111In-benzyl-EDTA monoclonal antibody on hepatic uptake and processing in mice. Cancer Res (1989) 0.79
Development of a hyperimmune anti-MUC-1 single chain antibody fragments phage display library for targeting breast cancer. Clin Cancer Res (1999) 0.79
Multicompartmental analysis of the kinetics of radioiodinated monoclonal antibody in patients with cancer. J Nucl Med (1986) 0.79
Dosimetric evaluation of copper-64 in copper-67-2IT-BAT-Lym-1 for radioimmunotherapy. J Nucl Med (1996) 0.78
Application of the linear-quadratic model to myelotoxicity associated with radioimmunotherapy. Eur J Nucl Med (1996) 0.78
Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: A comparative study. Int J Biol Markers (1996) 0.78
31P surface-coil NMR analysis of metabolic status in KHJJ tumors. Magn Reson Med (1985) 0.78
Assessment of circulation in the femoral head by 18F scintigraphy. J Nucl Med (1974) 0.78
Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A. Clin Cancer Res (1999) 0.78
Bronchoscopic location of bronchopleural fistula with xenon-133. J Nucl Med (1982) 0.78
Bone marrow and bone mineral scintigraphic studies in sickle cell disease. Br J Haematol (1973) 0.78
Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy. Clin Nucl Med (1995) 0.78
Comparison of three boundary detection methods for SPECT using Compton scattered photons. J Nucl Med (1988) 0.78
Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression. Cancer Res (1995) 0.77
Planar gamma camera quantitation of 123I, 99mTc or 111In in the liver and spleen of an abdominal phantom. Cancer Biother Radiopharm (1999) 0.77
Radioimmunolocalization of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: phase I study. J Nucl Med (1993) 0.77
Pharmacokinetics of radioiodinated streptokinase. J Nucl Med (1975) 0.77
Prevention of lower extremity venous thrombosis by early mobilization. Confirmation in patients with acute myocardial infarction by 125I-fibrinogen uptake and venography. Ann Intern Med (1976) 0.77
Phage library-derived human anti-TETA and anti-DOTA ScFv for pretargeting RIT. Hybridoma (1999) 0.77
A new era for radiolabeled antibodies in cancer? Curr Opin Immunol (1999) 0.77
67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma. Clin Cancer Res (1999) 0.76
Overview of radioimmunotherapy in advanced breast cancer using I-131 chimeric L6. Adv Exp Med Biol (1994) 0.76
Experience with 99mTc diphosphonate in studying vascularity of the femoral head. Surg Forum (1975) 0.76
Fluoride-18 scintigraphy in avascular necrotic disorders of bone. Clin Orthop Relat Res (1975) 0.76
Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts. J Nucl Med (1998) 0.76
Vascularity of the femoral head: 18fluorine scintigraphy validated with tetracycline labeling. Radiology (1975) 0.76
New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor. Hybridoma (1998) 0.76
Bone pain palliation. Cancer Biother Radiopharm (1998) 0.76
Determination of improved myocardial perfusion after aortocoronary bypass surgery by exercise rubidium-81 scintigraphy. Circulation (1976) 0.75
Enhancement of clinical radioimmunotherapy for cancer and the role of cytokines. J Natl Cancer Inst (1992) 0.75
Quo vadis radioimmune imaging? J Nucl Med (1990) 0.75
Noninvasive detection of regional myocardial ischemia using rubidium-81 and the scintillation camera: comparison with stress electrocardiography in patients with arteriographically documented coronary stenosis. Circulation (1975) 0.75
About the old and the new: gallium-67 scintigraphy to rituximab for lymphoma. Cancer Biother Radiopharm (1999) 0.75